Having trouble accessing articles? Reset your cache.

Gilead reports more HCV data, 1Q13 earnings

Gilead Sciences Inc. (NASDAQ:GILD) reported interim data from the Phase II LONESTAR trial evaluating a once-daily, oral fixed-dose combination of sofosbuvir plus ledipasvir ( GS-5885) to treat chronic HCV genotype 1 infection.

Read the full 326 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE